SABR for metastasis-directed therapy - what we've learned and what's to come

Affiliations

¹ Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA.
² Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA. Jeffrey.R.Olsen@cuanschutz.edu.

Comment

Tyler P Robin et al. Nat Rev Clin Oncol. 2020 Oct.

. 2020 Oct;17(10):593-594.

doi: 10.1038/s41571-020-0416-9.

¹ Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA.
² Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA. Jeffrey.R.Olsen@cuanschutz.edu.

No abstract available

Comment on

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Palma DA, et al. J Clin Oncol. 2020 Sep 1;38(25):2830-2838. doi: 10.1200/JCO.20.00818. Epub 2020 Jun 2. J Clin Oncol. 2020. PMID: 32484754 Free PMC article. Clinical Trial.

1. Hellman, S. & Weichselbaum, R. R. Oligometastases. J. Clin. Oncol. 13, 8–10 (1995). - DOI
1. Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670–691 (2017). - DOI
1. Pastorino, U. et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J. Thorac. Cardiovasc. Surg. 113, 37–49 (1997). - DOI
1. Palma, D. A. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J. Clin. Oncol. https://doi.org/10.1200/JCO.20.00818 (2020). - DOI - PubMed
1. Palma, D. A. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393, 2051–2058 (2019). - DOI